Chapter 115 – Initial Therapy of Parkinson's Disease
作者： Cathy Chuang , Cheryl Waters
DOI: 10.1016/B0-44-306557-8/50117-9
关键词:
摘要: The pharmacologic treatment of Parkinson's disease (PD) can be divided into two categories: neuroprotective and symptomatic. While the is still mild, one initial potential goal to slow down or stop progression disease. Such an approach uses purported agents, which may interfere with further degeneration neurons in substantia nigra. Although several agents are considered possibly based on theoretical experimental evidence, at present we have no therapy that definitely has been proven PD. Therefore, management PD focuses mainly symptomatic treatment, only diminish control symptoms but effect progression. A third possible restorative therapies, such as growth factors fetal stem cell transplantation. These will not discussed because they unavailable being studied both basic research clinical trials.
sci-hub.st 参考文章(12)
Ira Shoulson, , DATATOP: A decade of neuroprotective inquiry Annals of Neurology. ,vol. 44, ,(1998) , 10.1002/ANA.410440724
A. D. Korczyn, E. R. Brunt, J. P. Larsen, Z. Nagy, W. H. Poewe, S. Ruggieri, A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease Neurology. ,vol. 53, pp. 364- 370 ,(1999) , 10.1212/WNL.53.2.364
William J. Weiner, The initial treatment of Parkinson's disease should begin with levodopa. Movement Disorders. ,vol. 14, pp. 716- 724 ,(1999) , 10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q
G. Van Horn, M. C. Schiess, W. C. Koller, Immediate-release and controlled-release carbidopa/levodopa in PD A 5-year randomized multicenter study Neurology. ,vol. 55, pp. 156- 157 ,(1999) , 10.1212/WNL.55.1.156
Paolo Barone, D Bravi, F Bermejo–Pareja, R Marconi, J Kulisevsky, S Malagu, R Weiser, N Rost, Pergolide Monotherapy Study Group, Pergolide monotherapy in the treatment of early PD : A randomized, controlled study Neurology. ,vol. 53, pp. 573- 573 ,(1999) , 10.1212/WNL.53.3.573
Kedar N. Prasad, William C. Cole, Bipin Kumar, Multiple antioxidants in the prevention and treatment of Parkinson's disease. Journal of The American College of Nutrition. ,vol. 18, pp. 413- 423 ,(1999) , 10.1080/07315724.1999.10718878
S. Fahn, Is levodopa toxic Neurology. ,vol. 47, pp. 184- ,(1996) , 10.1212/WNL.47.6_SUPPL_3.184S
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease The New England Journal of Medicine. ,vol. 328, pp. 176- 183 ,(1993) , 10.1056/NEJM199301213280305
Olivier Rascol, David J Brooks, Amos D Korczyn, Peter P De Deyn, Carl E Clarke, Anthony E Lang, None, A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa The New England Journal of Medicine. ,vol. 342, pp. 1484- 1491 ,(2000) , 10.1056/NEJM200005183422004
R. Kurlan, D. Standaert, C. Casaceli, I. Shoulson, J. Seibyl, D. Amyot, R. Holloway, R. Rodnitzky, P. Tariot, J. Jankovic, L. Barclay, M. Harrigan, T. Shirley, I. Gardiner, S. Rast, A. Rajput, P. Rainey, K. Marek, A. Lang, A. Watts, S. Schuman, M. McDermott, A. Brocht, C. Kamp, B. Fussell, C. Weeks, C. O'Connell, L. Sutherland, M. Kurth, S. Daigneault, D. Day, K. Honsinger, K. Hildebrand, A. Shinaman, M. Brewer, S. Coe, R. Pahwa, S. Dillon, K. Hodgeman, E. Sime, D. Fontaine, M. Welsh, B. Ford, B. Pfeiffer, J. Dobson, D. Brown, S. Factor, J. Duff, C. Shults, C. Waters, F. Atassi, J. Hammerstad, M. Panisset, J. Hall, J. Hubble, E. Rost-ruffner, P. Lewitt, M. Tennis, F. Wooten, D. S. Russell, W. Weiner, D. Riley, R. Pfeiffer, O. Suchowersky, C. Stone, J. Miyasaki, M. Stacy, K. Kieburtz, S. Fahn, Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial JAMA. ,vol. 284, pp. 1931- 1938 ,(2000)